Capsule Summary Slidesets

Share

Program Content

Activities

  • GLOW: Ibr + Ven and MRD
    GLOW: MRD Outcomes After First-line Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab for Older/Unfit Patients With CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2021

    Expires: December 11, 2022

  • ELARA High-Risk RR FL
    Phase II ELARA: Extended Follow-up and Subgroup Analysis of Tisagenlecleucel in High-Risk R/R Follicular Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2021

    Expires: December 12, 2022

  • ZUMA-7
    Primary Analysis of ZUMA-7: Randomized Phase III Trial of 2L Axicabtagene Ciloleucel vs Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2021

    Expires: December 12, 2022

  • Valemetostat for R/R ATL
    Pivotal Phase II Trial of Valemetostat, an EZH1/EZH2 Inhibitor, in Patients With R/R Adult T-Cell Leukemia/Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2021

    Expires: December 13, 2022

  • CITADEL-205: Parsaclisib in R/R MCL
    CITADEL-205: Phase II Study of Parsaclisib in Patients With BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2021

    Expires: December 13, 2022

  • ELEVATE-RR AEs
    ELEVATE-RR: Characterization of BTKi-Related AEs in Acalabrutinib vs Ibrutinib in Previously Treated CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2021

    Expires: December 14, 2022

  • Parsaclisib in R/R FL
    CITADEL-203 Phase II Study of the PI3Kδ Inhibitor Parsaclisib in Patients With Relapsed/Refractory Follicular Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2021

    Expires: December 15, 2022

  • ASCEND 3-Yr Update
    3-Yr Follow-up of ASCEND Phase III Trial: Acalabrutinib vs Idelalisib/Rituximab or Bendamustine/Rituximab in R/R CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2021

    Expires: December 15, 2022

  • MRD Surveillance in DLBCL
    Prospective Study Evaluating MRD and CT Imaging Surveillance Following First-line Treatment in Patients With DLBCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2021

    Expires: December 15, 2022

  • Alliance 051701
    Alliance 051701: Randomized Phase II/III Trial of DA-EPOCH-R ± Venetoclax in Patients With Previously Untreated Double-Hit Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2021

    Expires: December 15, 2022

  • POLARIX: Polatuzumab vedotin
    POLARIX Trial of Polatuzumab Vedotin + R-CHP VS R-CHOP in Patients With Previously Untreated DLBCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2021

    Expires: December 16, 2022

  • BELINDA: Tisagenlecleucel in R/R NHL
    Phase III BELINDA Trial of Tisagenlecleucel vs Standard of Care as Second-line Treatment for R/R Aggressive B-Cell Non-Hodgkin Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2021

    Expires: December 16, 2022

  • SEQUOIA: zanubrutinib in CLL/SLL
    Phase III SEQUOIA Trial of Zanubrutinib vs Bendamustine and Rituximab in Previously Untreated CLL/SLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2021

    Expires: December 19, 2022

  • CAPTIVATE MRD Cohort 2-Yr Update
    CAPTIVATE MRD Cohort: 2-Yr Postrandomization Efficacy and Safety With First-Line Ibrutinib + Venetoclax in CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 21, 2021

    Expires: December 20, 2022

  • TRANSFORM: Liso-Cel in LBCL
    TRANSFORM: Lisocabtagene Maraleucel vs Salvage Chemotherapy Followed by ASCT as Second-Line Treatment in Relapsed/Refractory Large B-Cell Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 21, 2021

    Expires: December 20, 2022

  • MK-1026 in CLL/SLL
    Phase II Study of Novel BTK Inhibitor MK-1026 in Patients With R/R CLL/SLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 21, 2021

    Expires: December 20, 2022

  • Mosunetuzumab in R/R FL
    Mosunetuzumab, a CD20 x CD3 Bispecific Antibody, in R/R Follicular Lymphoma With ≥2 Previous Therapies: Pivotal Phase II Trial Results
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 22, 2021

    Expires: December 21, 2022

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation